Differenzialdiagnose bei Myalgien

Zusammenfassung

Myalgien können als unspezifisches Symptom bei einer Vielzahl neurologischer und anderer Erkrankungen auftreten. Häufig sind diese Schmerzen nicht durch eine primäre Schädigung des Skelettmuskels selbst verursacht, sondern Begleitsymptome unterschiedlicher Erkrankungen. Primäre muskuläre Ursachen müssen jedoch bedacht werden, um entsprechend zu beraten und eine angemessene Therapie anbieten zu können.

In der vorliegenden Arbeit werden Myopathien und primär nicht muskuläre Erkrankungen im Hinblick auf die Differenzialdiagnose von Muskelschmerzen vorgestellt.

Summary

Myalgia is a common non specific symptom associated with a variety of neurological and other diseases. Often muscle pain is not caused by direct damage of the skeletal muscle itself, but is rather a non specific accompanying feature of different diseases. Still, disorders of the skeletal muscle must be considered to provide adequate counselling and therapy for these patients.

Here we summarise myopathies and other disorders not due to primary damage of the skeletal muscle in the context of the differential diagnosis of muscle pain.

Schlüsselwörter

Myalgie - Muskelschmerz - Differenzialdiagnose

Keywords

Myalgia - muscle pain - differential diagnosis

• Literatur

• 1 Hays AP, Gamboa ET. Acute viral myositis. In: Myology. Engel AG. (Ed). New York: McGraw Hill; 1994: 1399-418.
• 2 Müller-Felber W. et al. Myositis in Lyme borreliosis: an immunohistochemical study of seven patients. J Neurol Sci 1993; 118: 207-12.
• 3 Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
• 4 Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403-7.
• 5 Heuss D. et al. Myopathological findings in interstitial myositis in type II polyendocrine autoimmune syndrome (Schmidt’s syndrome). Neurol Res 1995; 17: 233-7.
• 6 Angelini C. et al. Clinical varieties of carnitine and carnitine palmitoyltransferase deficiency. Clin Biochem 1987; 20: 1-7.
• 7 Fingerhut R. et al. Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific. Clin Chem 2001; 47: 1763-8.
• 8 Gempel K. et al. Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis 2002; 25: 17-27.
• 9 Morisaki T. et al. Molecular basis of AMP deaminase deficiency in skeletal muscle. Proc Natl Acad Sci USA 1992; 89: 6457-61.
• 10 Gross M. et al. A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population. Neuromuscul Disord 2002; 12: 558-65.
• 11 Baumeister FA. et al. Myoadenylate deaminase deficiency with severe rhabdomyolysis. Eur J Pediatr 1993; 152: 513-5.
• 12 Gold R. et al. Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. Muscle Nerve 1992; 15: 214-8.
• 13 Rosenfeld J, Sloan-Brown K, George AL. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann Neurol 1997; 42: 811-4.
• 14 Ricker K. et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44: 1448-52.
• 15 Schneider C, Reiners K, Toyka KV. Myotone Dystrophy (DM/Curschmann-Steinert-Erkrankung) und proximale myotone Myopathie (PROMM/Ricker-Syndrom). Myotone Muskelerkrankungen mit multisystemischen Manifestationen. Nervenarzt 2001; 72: 618-24.
• 16 Day JW. et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60: 657-64.
• 17 George A. et al. Musculosceletal pain in myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938-42.
• 18 Schneider C, Koch MC. Multisystemische myotone Myopathien, in Neuromuskuläre Erkrankungen. Pongratz D. (Ed), Köln: Deutscher Ärzte-Verlag; 2003: 117-39.
• 19 Vihola A. et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/ DM2. Neurology 2003; 60: 1854-7.
• 20 Lochmüller H. et al. Exercise-induced myalgia in hypothyroidism. Clin Investig 1993; 71: 999-1001.
• 21 Wolfe F. et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
• 22 Le Quintrec JS, Le Quintrec JL. Drug induced myopathies. Bailliere’s Clinical Rheumatology 1991; 5: 21-38.
• 23 Stoltenburg-Didinger G, Neuhaus GA. Toxische Ursachen von Muskelschmerzen. Internist (Berl) 1987; 28: 596-605.
• 24 Sieb JP, Gillessen T. Iatrogenic and toxic myopathies. Muscle Nerve 2003; 27: 142-56.
• 25 Hengstman GJ. et al. Myositis during long-term interferon-alpha treatment. Neurology 2000; 54: 2186.
• 26 Döser S. et al. Empfehlung zur Statintherapie im Alter. Internist (Berl) 2004; 45: 1053-62.
• 27 Pasternak RC. et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 2002; 33: 2337-41.
• 28 Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. Jama 2003; 289: 1681-90.
• 29 Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995; 7: 560-7.
• 30 Sullivan EA. et al. The natural history of eosinophilia-myalgia syndrome in a tryptophan-exposed cohort in South Carolina. Arch Intern Med 1996; 156: 973-9.
• 31 Meinck HM. Das Stiff-man-Syndrom aus neurologischer Sicht. Internist (Berl) 2000; 41: 455-9.
• 32 Wessig C. et al. Neuropathology and binding studies in anti-amphiphysin-associated stiff-person syndrome. Neurology 2003; 61: 195-8.
• 33 Vincent A. Understanding neuromyotonia. Muscle Nerve 2000; 23: 655-7.
• 34 Zierz S, Jerusalem F. Neuromyotonie, in Muskelerkrankungen. Stuttgart: Georg Thieme Verlag; 2003: 186-7.
• 35 Karpati G. et al. Myopathy caused by a deficiency of Ca²⁺-adenosine triphosphatase in sarcoplasmic reticulum (Brody’s disease). Ann Neurol 1986; 20: 38-49.
• 36 Odermatt A. et al. Mutations in the gene-encoding SERCA1, the fast-twitch skeletal muscle sarcoplasmic reticulum Ca²⁺ ATPase, are associated with Brody disease. Nat Genet 1996; 14: 191-4.
• 37 Taylor DJ. et al. Ca²⁺-ATPase deficiency in a patient with an exertional muscle pain syndrome. J Neurol Neurosurg Psychiatry 1988; 51: 1425-33.
• 38 Ricker K, Moxley RT, Rohkamm R. Rippling muscle disease. Arch Neurol 1989; 46: 405-8.
• 39 Alberca R. et al. Increased mechanical muscle irritability syndrome. Acta Neurol Scand 1980; 62: 250-4.
• 40 Roke ME. et al. Myopathy in primary systemic amyloidosis. Can J Neurol Sci, 1988; 15: 314-6.
• 41 Zierz S, Jerusalem F. Amyloidmyopathie, in Muskelerkrankungen. Stuttgart: Georg Thieme Verlag; 2003: 339.
• 42 Troost D. et al. Immunohistological alterations in muscle of patients with amyotrophic lateral sclerosis: mononuclear cell phenotypes and expression of MHC products. Clin Neuropathol 1992; 11: 115-20.
• 43 Dalakas M. Postpolio syndrome. Curr Opin Rheumatol 1990; 2: 901-7.
• 44 Jubelt B, Agre JC. Characteristics and management of postpolio syndrome. Jama 2000; 284: 412-4.
• 45 Ropper AH, Shahani BT. Pain in Guillain-Barre syndrome. Arch Neurol 1984; 41: 511-4.
• 46 Pentland B, Donald SM. Pain in the Guillain-Barre syndrome: a clinical review. Pain 1994; 59: 159-64.
• 47 Pearn J. Neurology of ciguatera. J Neurol Neurosurg Psychiatry 2001; 70: 4-8.
• 48 Ruprecht K, Rieckmann P, Giess R. Ciguatera: Klinische Bedeutung eines marinen Neurotoxins. Dtsch Med Wochenschr 2001; 126: 812-4.
• 49 Blume C. et al. Die CiguateraVergiftung – wachsende differentialdiagnostische Bedeutung im Zeitalter des Fernreisetourismus. Med Klin (Munich) 1999; 94: 45-9.
• 50 Arendt G, Grabensee B. Ciguatera: Klinische Bedeutung eines marinen Neurotoxins. Dtsch Med Wochenschr 2001; 126: 1381-2.